ASCO GI 2023 Conference Coverage
Playback speed
10 seconds
ASCO GI 2023 Debate: For a Fit Patient With Unresectable Metastatic RAS Wild-Type Sigmoid Colon Adenocarcinoma, 1L EGFR Antibody Is an Essential Treatment - PRO
By
ASCO GI 2023 Conference Coverage
FEATURING
Kai-Keen Shiu
By
ASCO GI 2023 Conference Coverage
FEATURING
Kai-Keen Shiu
149 views
February 6, 2023
Comments 0
Login to view comments.
Click here to Login
Videos